Bradyco Inc. Acquires New Position in Novartis AG (NYSE:NVS)

Bradyco Inc. purchased a new stake in Novartis AG (NYSE:NVS - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 7,191 shares of the company's stock, valued at approximately $700,000.

A number of other institutional investors have also made changes to their positions in the business. Centaurus Financial Inc. grew its holdings in Novartis by 1.7% in the 3rd quarter. Centaurus Financial Inc. now owns 5,728 shares of the company's stock valued at $659,000 after buying an additional 98 shares during the last quarter. WealthPlan Investment Management LLC boosted its position in shares of Novartis by 1.1% in the third quarter. WealthPlan Investment Management LLC now owns 9,494 shares of the company's stock valued at $1,092,000 after acquiring an additional 100 shares during the period. Bryn Mawr Capital Management LLC grew its stake in shares of Novartis by 0.8% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 12,884 shares of the company's stock worth $1,254,000 after acquiring an additional 100 shares during the last quarter. Rothschild Investment LLC increased its position in Novartis by 0.6% during the fourth quarter. Rothschild Investment LLC now owns 16,682 shares of the company's stock worth $1,623,000 after acquiring an additional 101 shares during the period. Finally, Avidian Wealth Enterprises LLC raised its stake in Novartis by 1.3% during the 3rd quarter. Avidian Wealth Enterprises LLC now owns 7,913 shares of the company's stock valued at $910,000 after purchasing an additional 102 shares during the last quarter. 13.12% of the stock is currently owned by institutional investors.

Novartis Price Performance

NVS stock traded down $3.99 during midday trading on Tuesday, reaching $111.48. 2,021,182 shares of the company's stock traded hands, compared to its average volume of 2,066,343. The company has a quick ratio of 0.84, a current ratio of 1.04 and a debt-to-equity ratio of 0.48. The company has a market cap of $227.87 billion, a price-to-earnings ratio of 18.96, a PEG ratio of 1.70 and a beta of 0.53. The company has a 50-day simple moving average of $104.38 and a two-hundred day simple moving average of $107.87. Novartis AG has a 1-year low of $92.35 and a 1-year high of $120.92.

Remove Ads

Novartis (NYSE:NVS - Get Free Report) last released its quarterly earnings results on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. On average, analysts anticipate that Novartis AG will post 8.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on NVS. StockNews.com upgraded shares of Novartis from a "buy" rating to a "strong-buy" rating in a research report on Saturday, February 8th. UBS Group restated a "neutral" rating on shares of Novartis in a research note on Thursday, February 13th. Morgan Stanley assumed coverage on Novartis in a report on Wednesday, February 12th. They issued an "underweight" rating for the company. HSBC lowered Novartis from a "hold" rating to a "reduce" rating in a report on Wednesday, December 4th. Finally, Erste Group Bank reiterated a "hold" rating on shares of Novartis in a research note on Tuesday, November 19th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $123.38.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.